SK C&C to promote AI healthcare for brain diseases

South Korea's SK C&C announced on Thursday that it signed a strategic business agreement with Neurophet, a cloud-based AI platform for brain image analysis, to expand its brain disease AI.

Established in 2016, Neurophet researches and develops brain imaging analysis solutions covering the entire cycle of brain diseases, including diagnosis, treatment guidance, and therapy, based on AI technology.

The company utilizes its AI engine "Neurophet SegEngine" to rapidly segment brain images and precisely analyze different brain structures for various brain disease solution products.

Under this agreement, the two companies will first introduce a "Brain Disease Medical AI Total Service" that combines their respective AI solutions. In particular, in the field of cerebral infarction, they will integrate Neurophet's AI for cerebral infarction diagnosis, which is under development, with SK C&C's "Medical Insight Plus Brain Hemorrhage" solution for diagnosing brain hemorrhages based on non-contrast computerized tomography (CT) and other non-contrast CT-based brain ischemia diagnosis solutions.

The two companies plan to actively cooperate in marketing efforts targeting the global market, starting with the Radiological Society of North America (RSNA), the largest medical conference that will be held in Chicago on Nov. 26.

Write to Jin-Won Kim at jin1@hankyung.com